文献速递功能神经外科

丘脑刺激治疗肌阵挛-肌张力障碍综合征:五例报告及长期随访

Thalamus Stimulation for Myoclonus Dystonia Syndrome: Five Cases and Long-Term Follow-up.
PubMed 文献 · World Neurosurg · 2018-11-10

本文报告5例以肌阵挛为主的肌阵挛-肌张力障碍综合征(MDS)患者接受丘脑腹中间核(Vim)脑深部电刺激(DBS)的长期随访结果,其中2例SGCE基因突变阳性、3例阴性。平均随访50个月,肌阵挛改善率92.7%,Burke-Fahn-Marsden肌张力障碍评定量表(BFMDRS)运动评分平均改善71.4%、致残评分平均改善75.8%。作者认为Vim DBS对MDS可能是安全有效的治疗选择。

要点

  • 5例以肌阵挛为主的MDS患者接受Vim DBS,平均随访50个月。
  • 肌阵挛改善率92.7%,BFMDRS运动评分改善71.4%、致残评分改善75.8%。
  • 作者认为无论SGCE突变与否,肌阵挛为主的MDS可优先考虑单用Vim DBS。

核心结论

  • 本研究提示Vim DBS对MDS患者可能是安全有效的治疗选择。
  • 作者认为对于以肌阵挛为主的MDS患者,无论是否检出SGCE突变,单用Vim DBS可能更可取。
  • 作者提出Vim DBS后出现进行性肌张力障碍时可加用苍白球内侧部DBS。

研究设计与样本

  • 研究纳入2例SGCE突变阳性和3例SGCE突变阴性、以肌阵挛为主要表现的患者,均接受Vim DBS。
  • 术前和术后采用统一肌阵挛评定量表和Burke-Fahn-Marsden肌张力障碍评定量表(BFMDRS)进行评估。

主要发现

  • 平均随访50个月期间,肌阵挛改善率为92.7%。
  • BFMDRS运动评分平均改善71.4%,BFMDRS致残评分平均改善75.8%。

临床怎么用

  • 作者认为Vim DBS对MDS可能是安全有效的治疗选择。
  • 作者认为以肌阵挛为主的MDS患者无论SGCE突变状态如何,单用Vim DBS可能更可取。
  • 作者提出Vim DBS后出现进行性肌张力障碍时可加用苍白球内侧部DBS。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Myoclonic dystonia syndrome (MDS) is a rare inherited movement disorder characterized by the coexistence of myoclonic jerks and dystonia. Deep brain stimulation (DBS) is a promising treatment for patients with MDS that targets the globus pallidus internus or ventral intermediate nucleus (Vim) of the thalamus. However, there are few studies regarding the long-term effects of Vim DBS in patients with MDS and even fewer in those without gene mutations. METHODS: Two positive and three negative SGCE mutation patients presenting with predominant myoclonus underwent Vim DBS. The Unified Myoclonus Rating Scale and the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) were assessed pre- and postoperation. RESULTS: Over an average follow-up period of 50 months, the myoclonus improvement rate was 92.7%. The average improvement in the BFMDRS motor score was 71.4% and the average improvement in the BFMDRS disabling score was 75.8%. CONCLUSIONS: This study suggests that Vim DBS can be a safe and effective treatment option for patients with MDS. Vim DBS alone may be preferable for patients with myoclonus-dominated MDS regardless of the identification of an SGCE mutation. Additional globus pallidus internus DBS may be used for progressive dystonia after Vim DBS.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Zhang YQ, Wang JW, Wang YP, et al. Thalamus Stimulation for Myoclonus Dystonia Syndrome: Five Cases and Long-Term Follow-up. World Neurosurg. 2018. PMID: 30419400. doi:10.1016/j.wneu.2018.10.177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。